Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

Documenti analoghi

• Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants
  di: Yan‐ou Yang, et al.
  Pubblicazione: (2025)
• Evaluation of clinical cardiac safety of zilurgisertib, an activin receptor‐like kinase‐2 (ALK2) inhibitor, in healthy participants
  di: Yan‐ou Yang, et al.
  Pubblicazione: (2025)
• Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib
  di: Martha Gonzalez, et al.
  Pubblicazione: (2025)
• Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria
  di: Valérie Cosson, et al.
  Pubblicazione: (2025)
• Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment
  di: Megumi Iwai, et al.
  Pubblicazione: (2025)